您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2014, Vol. 52 ›› Issue (9): 34-38.doi: 10.6040/j.issn.1671-7554.0.2014.102

• 基础医学 • 上一篇    下一篇

人参皂苷Re对人脐静脉内皮细胞PARP-1表达的抑制作用

陈建华1, 朱邦豪2   

  1. 1. 川北医学院药学院药理教研室, 四川 南充 637000;
    2. 中山大学中山医学院药理教研室, 广东 广州 510000
  • 收稿日期:2014-02-27 修回日期:2014-09-05 出版日期:2014-09-10 发布日期:2014-09-10

Inhibiting Effect of ginsenoside Re on the expression of PARP-1 in human umbilical vein endothelial cell

CHEN Jianhua1, ZHU Banghao2   

  1. 1. Department of Pharmacology, School of Pharmacy, North Sichuan Medical University, Nanchong 637000, Sichuan, China;
    2. Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510000, Guangdong, China
  • Received:2014-02-27 Revised:2014-09-05 Online:2014-09-10 Published:2014-09-10
  • Contact: 朱邦豪。E-mail:zhubh@mail.sysu.edu.cn E-mail:zhubh@mail.sysu.edu.cn

PDF (PC)

131

摘要： 目的 筛选对多聚二磷酸腺苷核糖聚合酶-1（PARP-1）有潜在抑制作用的中药单体，研究中药单体对人脐静脉内皮细胞（HUVEC）PARP-1表达的抑制作用。方法 在中国天然产物数据库中通过计算机虚拟筛选初步得到对PARP-1有潜在抑制作用的6种中药单体，对加入中药单体的细胞分设高、低剂量组，浓度分别为1×10-4、1×10-6 mol/L，另将加入3-氨基苯甲酰胺（3-AB）的细胞作为阳性对照组、只加2×10-4 mol/L ONOO-的细胞作为模型组。Western blotting检测PARP-1表达。若待筛药物对PARP-1表达有抑制作用，则以1×10-4～1×10-8 mol/L的药物进行浓度依赖性实验。结果 1×10-4、1×10-6 mol/L人参皂苷Re与1×10-4 mol/L人参皂苷Rb1对ONOO-引起的PARP-1激活有抑制作用。1×10-4～1×10-8 mol/L人参皂苷Re对 PARP-1 的表达有明显的抑制作用，且呈现出剂量依赖性（P<0.05）。结论 人参皂甙Re对HUVEC上ONOO-激活的PARP-1蛋白表达有抑制作用，对ONOO-引起的细胞损伤具有保护作用，其效应呈现出剂量依赖性。

关键词: 中药单体, ONOO-, 人脐静脉内皮细胞, 多聚二磷酸腺苷核糖聚合酶-1

Abstract: Objective To screen herbal monomers with potential inhibition on poly(ADP-ribose)polymerase-1 (PARP-1), and to study their inhibiting effects on PARP-1 expression in human umbilical vein endothelial cell (HUVEC). Methods Six herbal monomers which might have potential inhibiting effect on PARP-1 were screened by computer visual screening in Chinese Natural Product Database. The cells were divided into the following groups:high (1×10-4 mol/L) and low (1×10-6 mol/L) doses groups for the herbal monomers, the 3-aminobenzamide(3-AB) positive control group and model group. Western blotting was used to test the expression of PARP-1. When the tested drugs exhibited inhibiting effects on PARP-1 expression, the drug-dependent experiments would be carried out with the drug concentration being 1×10-4 to 1×10-8 mol/L. Results 1×10-4 and 1×10-6 mol/L ginsenoside Re and 1×10-4 mol/L ginsenoside Rb1 had inhibiting effect on PARP-1 activated by ONOO-. 1×10-4 to 1×10-8 mol/L ginsenoside Re had obvious inhibiting effect on PARP-1 expression in a dose-dependent manner (P<0.05). Conclusion Ginsenoside Re can inhibit protein expression of PARP-1 activated by ONOO- on HUVECs and has protecting effect on ONOO--induced injury in a dose-dependent manner.

Key words: Human umbilical vein endothelial cell, Herbal monomer, Poly(ADP-ribose)polymerase-1, ONOO-

中图分类号: 

  • R965.1
[1] Liscio P, Camaioni E, Carotti A, et al. From polyphar-macology to target specificity: the case of PARP inhibitors[J]. Curr Top Med Chem, 2013, 13(23): 2939-2954.
[2] 覃冬, 康刚劲. 3-氨基苯甲酰胺影响糖尿病大鼠晶状体上皮细胞NF-κB表达的免疫组化研究[J]. 重庆医学, 2011, 40(24): 2438-2440. QIN Dong, KANG Gangjin.The immunohistochemical study of the expression of NF-κB in the lens epithelial cells in diabetic rats by 3-AB[J]. Chongqing Medicine,2011,40 (24): 2438-2440.
[3] Wang G, Huang X, Li Y, et al. PARP-1 inhibitor, DPQ, attenuates LPS-induced acute lung injury through inhibiting NF-kappaB-mediated inflammatory response[J]. PLoS One, 2013, 8(11): e79757.
[4] 张敬敬, 王哲, 田永杰, 等. PJ34对卵巢癌C13*细胞生长活性及耐药性的影响[J]. 山东大学学报:医学版, 2012, 1(1): 46-50. ZHANG Jingjing, WANG Zhe, TIAN Yongjie, et al. Effects of PJ34 on growth activity and cisplatin resistance of ovarian cancer C13* cells[J]. Journal of Shandong University: Health Sciences, 2012, 1(1): 46-50.
[5] Daniel R A, Rozanska A L, Thomas H D, et al. Inhibi-tion of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma[J]. Clin Cancer Res, 2009, 15(4): 1241-1249.
[6] 胡珀, 宋丽君, 王飏, 等. 聚腺苷二磷酸核糖聚合酶抑制剂的临床研究进展[J]. 中国新药与临床杂志, 2012, 31(1): 1-6. HU Po, SONG Lijun, WANG Yang, et al. Clinical development of poly(ADP-ribose) polymerase inhibitors[J]. Chin J New Drugs Clin Rem, 2012, 31(1): 1-6.
[7] Yuan K, Sun Y, Zhou T, et al. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy[J]. Clin Cancer Res, 2013, 19(17): 4750-4759.
[8] Lee J M, Ledermann J A, Kohn E C. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies[J]. Ann Oncol, 2014, 25(1): 32-40.
[9] Hannigan K, Kulkarni S S, Bdzhola V G, et al. Identification of novel PARP-1 inhibitors by structure-based virtual screening[J]. Bioorg Med Chem Lett, 2013, 23(21): 5790-5794.
[10] 柳军, 张陆勇. 聚腺苷二磷酸核糖聚合酶-1抑制剂高通量筛选模型[J]. 中国药理学通报, 2007, 23(1): 124-127. LIU Jun, ZHANG Luyong. High throughput screening model for poly(ADP-ribose) polymerase-1 inhibitor[J]. Chinese Pharmacological Bulletin, 2007, 23(1): 124-127.
[11] Gu J, Gui Y, Chen L, et al. Use of natural products as chemical library for drug discovery and network pharmacology[J]. PLoS One, 2013, 8(4): e62839.
[12] Gebhard C, Stahli B E, Shi Y, et al. Poly(ADP-ribose) polymerase-1 protects from oxidative stress induced endothelial dysfunction[J]. Biochem Biophys Res Commun, 2011, 414(4): 641-646.
[13] Zhang L Q, Qi G X, Jiang D M, et al. Increased poly(ADP-ribosyl)ation in peripheral leukocytes and the reperfused myocardium tissue of rats with ischemia/reperfusion injury: prevention by 3-aminobenzamide treatment[J]. Shock, 2012, 37(5): 492-500.
[14] Mukhopadhyay P, Rajesh M, Cao Z, et al. Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis[J]. Hepatology, 2014, 59(5): 1998-2009.
[15] Cheung A, Zhang J. A scintillation proximity assay for poly(ADP-ribose) polymerase[J]. Anal Biochem, 2000, 282(1): 24-28.
[16] Lee S, Koo H N, Lee B H. Development of a miniaturized assay for the high-throughput screening program for poly(ADP-ribose) polymerase-1[J]. Methods Find Exp Clin Pharmacol, 2005, 27(9): 617-622.
[17] Narwal M, Fallarero A, Vuorela P, et al. Homogeneous screening assay for human tankyrase[J]. J Biomol Screen, 2012, 17(5): 593-604.
[18] Xie J T, Shao Z H, Vanden Hoek T L, et al. Antioxidant effects of ginsenoside Re in cardiomyocytes[J]. Eur J Pharmacol, 2006, 532(3): 201-207.
[19] Zhou X M, Cao Y L, Dou D Q. Protective effect of ginsenoside-Re against cerebral ischemia/reperfusion damage in rats[J]. Biol Pharm Bull, 2006, 29(12): 2502-2505.
[20] Ford A L, Lee J M. Climbing STAIRs towards clinical trials with a novel PARP-1 inhibitor for the treatment of ischemic stroke[J]. Brain Res, 2011, 1410:120-121.
[1] 王晓磊 张海涛 张辉 郭成浩. 舒血宁注射液对高碘致培养血管内皮细胞损伤的保护作用[J]. 山东大学学报(医学版), 2209, 47(6): 38-.
[2] 刘辉, 陈桐帅, 李娜, 王舒健, 李静媛, 卜培莉. Sirt3对人脐静脉内皮细胞衰老的影响[J]. 山东大学学报（医学版）, 2015, 53(5): 41-45.
[3] 吴明绘，朱清，岳欣. 血管紧张素Ⅱ通过NF-κB信号传导途径促进人脐静脉内皮细胞内皮脂肪酶表达[J]. 山东大学学报(医学版), 2013, 51(06): 11-14.
[4] 刘文1，高聆2，于春晓1，王佳3，范右飞1，张媛1，管庆波1，赵家军1. 硫氢化钠对高浓度葡萄糖环境下原代人脐静脉内皮细胞的影响[J]. 山东大学学报(医学版), 2011, 49(7): 15-.
[5] 魏秀娟1，吴逸南1，姜虹2，苗青3，王荣2. 黄芪在高糖环境下对人脐静脉内皮细胞Apelin/APJ表达的影响[J]. 山东大学学报(医学版), 2010, 48(4): 10-14.
[6] 刘桂林1，窦迎春2，刘粉叶3，张晴4，任敏5，张继东5. 三七总皂苷对oxLDL诱导的人脐静脉内皮细胞CD40, VCAM-1表达的影响[J]. 山东大学学报(医学版), 2010, 48(10): 14-19.
[7] 王晓磊 张海涛 张辉 郭成浩. 舒血宁注射液对高碘致培养血管内皮细胞损伤的保护作用[J]. 山东大学学报(医学版), 2009, 47(6): 38-.
[8] 窦姗姗1 ， 邓景惕1 ，季冉1 ，扈燕来1 ，张伟红2 ，张立平1
. 辛伐他汀对人脐静脉内皮细胞分泌的细胞因子
TNFα、IL6及uPA/uPAR的抑制作用[J]. 山东大学学报(医学版), 2009, 47(04): 1-4.
[9] 王晓磊,徐丽雅,张海涛,李加美,郭成浩 . 不同碘浓度对培养血管内皮细胞增殖的影响[J]. 山东大学学报(医学版), 2007, 45(3): 310-312.
[10] 刘真真,周亚滨,唐　伟,李树英,吴建敏,程轶喆,齐　眉,王　红,刘　娟,于　晗. 巨细胞病毒感染致人脐静脉内皮细胞E选择素时序性的表达[J]. 山东大学学报(医学版), 2007, 45(2): 124-126.
[11] 吴建敏,周亚滨,程轶?,李树英,唐伟,赵蔚明,贾继辉,栾怡,齐眉,王红,刘娟,于晗,于修平. 巨细胞病毒感染人脐静脉内皮细胞后RAGEmRNA的时序性表达及其意义[J]. 山东大学学报(医学版), 2006, 44(8): 757-759.
[12] 李加美,金鲁明,张海涛,徐丽雅,郭成浩. 不同氟浓度对培养血管内皮细胞损伤的研究[J]. 山东大学学报(医学版), 2006, 44(10): 1014-1016.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发